Pros and Cons of Upfront Quadruple Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction.
作者信息
Reddy Yogesh, Pereira Naveen L
机构信息
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Mayo Clin Proc. 2025 Mar;100(3):420-423. doi: 10.1016/j.mayocp.2024.12.005.
Abstract
摘要
相似文献
1
Pros and Cons of Upfront Quadruple Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction.射血分数降低的新诊断心力衰竭患者早期四重药物治疗的利弊
Mayo Clin Proc. 2025 Mar;100(3):420-423. doi: 10.1016/j.mayocp.2024.12.005.
2
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure.新诊断心力衰竭患者快速起始四联疗法的资格和预期获益。
JACC Heart Fail. 2024 Aug;12(8):1365-1377. doi: 10.1016/j.jchf.2024.03.001. Epub 2024 Mar 25.
3
Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction.医疗治疗方案对新诊断的射血分数降低的心力衰竭患者的影响。
Clin Res Cardiol. 2024 Aug;113(8):1171-1182. doi: 10.1007/s00392-023-02241-0. Epub 2023 Jun 21.
4
Beyond quadruple therapy: the potential roles for ivabradine, vericiguat, and omecamtiv mecarbil in the therapeutic armamentarium.超越四联疗法：伊伐布雷定、维立西呱、奥马曲拉在治疗武器库中的潜在作用。
Heart Fail Rev. 2024 Sep;29(5):949-955. doi: 10.1007/s10741-024-10412-y. Epub 2024 Jun 29.
5
Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction.心力衰竭伴射血分数降低的综合四联疗法的成本效益分析。
JACC Heart Fail. 2023 May;11(5):541-551. doi: 10.1016/j.jchf.2023.01.004. Epub 2023 Mar 1.
6
Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score-matched analysis.射血分数降低的急性失代偿性心力衰竭患者早期应用四联疗法：一项倾向评分匹配分析。
ESC Heart Fail. 2025 Aug;12(4):2814-2826. doi: 10.1002/ehf2.15286. Epub 2025 Apr 15.
7
PCI has no role in patients with heart failure and reduced ejection fraction: pros and cons.经皮冠状动脉介入治疗对射血分数降低的心力衰竭患者无效：利弊分析
EuroIntervention. 2023 Dec 18;19(11):e887-e889. doi: 10.4244/EIJ-E-23-00035.
8
Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3.射血分数降低性心力衰竭恶化的管理：美国心脏病学会焦点研讨会 3/3。
J Am Coll Cardiol. 2023 Aug 8;82(6):559-571. doi: 10.1016/j.jacc.2023.04.057.
9
Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States.美国射血分数降低的心力衰竭管理中四联疗法的成本效益。
Circ Cardiovasc Qual Outcomes. 2023 Jun;16(6):e009793. doi: 10.1161/CIRCOUTCOMES.122.009793. Epub 2023 Jun 6.
10
Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.心力衰竭射血分数降低：超越四联疗法和当前治疗策略的医学治疗方法，具有成为治疗武器库一部分的潜力。
Int J Mol Sci. 2024 Mar 7;25(6):3113. doi: 10.3390/ijms25063113.
本文引用的文献
1
Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.达格列净与糖尿病或心力衰竭无关的心肌梗死。
NEJM Evid. 2024 Feb;3(2):EVIDoa2300286. doi: 10.1056/EVIDoa2300286. Epub 2023 Nov 11.
2
Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of and Cardiac Fibrosis.近期起病扩张型心肌病的心肌恢复：和心肌纤维化的作用。
Circ Res. 2023 Oct 27;133(10):810-825. doi: 10.1161/CIRCRESAHA.123.323200. Epub 2023 Oct 6.
3
Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.达格列净治疗射血分数改善的心力衰竭：DELIVER 试验的预设分析。
Nat Med. 2022 Dec;28(12):2504-2511. doi: 10.1038/s41591-022-02102-9. Epub 2022 Dec 15.
4
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.升阶梯治疗急性心力衰竭指南导向的药物治疗的安全性、耐受性和疗效（STRONG-HF）：一项多中心、开放标签、随机试验。
Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
5
Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.沙库巴曲缬沙坦对比雷米普利对急性心肌梗死后心脏结构和功能的影响：PARADISE-MI 超声心动图子研究。
Circulation. 2022 Oct 4;146(14):1067-1081. doi: 10.1161/CIRCULATIONAHA.122.059210. Epub 2022 Sep 9.
6
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净治疗急性心力衰竭住院患者的多中心随机试验。
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
7
Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.沙库巴曲缬沙坦对比标准药物治疗对射血分数保留心力衰竭患者血浆 NT-proBNP 浓度和亚极量运动能力的影响：PARALLAX 随机临床试验。
JAMA. 2021 Nov 16;326(19):1919-1929. doi: 10.1001/jama.2021.18463.
8
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.沙库巴曲缬沙坦在心力衰竭射血分数谱中的应用。
Circulation. 2020 Feb 4;141(5):352-361. doi: 10.1161/CIRCULATIONAHA.119.044586. Epub 2019 Nov 17.
9
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
10
Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.射血分数保留和降低的心衰患者射血分数的纵向变化。
Circ Heart Fail. 2012 Nov;5(6):720-6. doi: 10.1161/CIRCHEARTFAILURE.111.966366. Epub 2012 Aug 30.
Zotero 插件